European CHMP recommends approval of licence extension of remdesivir (Veklury)

The licence extension is for treatment of COVID-19 in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).

Source:

European Medicines Agency